Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, drugmaker Eli Lilly (NYSE: LLY) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Lilly's business and see what CAPS investors are saying about the stock right now.

Lilly facts

Headquarters (Founded) Indianapolis (1876)
Market Cap $45.5 billion
Industry Pharmaceuticals
Trailing-12-Month Revenue $23.4 billion
Management Chairman/CEO John Lechleiter
CFO Derica Rice
Return on Capital (Average, Past 3 Years) 23%
Cash/Debt $6.7 billion / $6.7 billion
Dividend Yield 5%

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 93% of the 1,366 members who have rated Lilly believe the stock will outperform the S&P 500 going forward. These bulls include DSmod and witness1260.

Late last month, DSmod tapped Lilly as an enticing way to make some income: "Historically low price for a solid company with a good dividend to tide you over while you wait for better times. I also like that because it is a drug developer, LLY's success is not necessarily bound to the economy."

Currently, Lilly even sports a particularly paltry P/E of 9. That represents a clear discount to big pharma plays such as Johnson & Johnson (NYSE: JNJ) (16), Novartis (NYSE: NVS) (15), and Pfizer (NYSE: PFE) (19).

CAPS member witness1260 elaborates on the bargain opportunity:

Look, I can see why people might be a little worried about Eli Lilly. They have a lot of debt and have posted operating losses the past few years. But they're on the right track. [R]evenues continue to grow and they continue to invest in growth. Plus, they beat out the industry across the board, notably in the efficiency categories and in gross margin and dividend yield. I think ... that long term, this stock will catch up to the S&P.

What do you think about Lilly, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!  

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Johnson & Johnson, Novartis, and Pfizer and creating a diagonal call position in Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days.

We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.